A comparative effectiveness study analyzed response to anemia supportive treatment for patients with multiple myeloma or lymphoma, published in Supportive Care in Cancer (online November 7, 2017; doi:10.1007/s00520-017-3948-5).

Read More

Conferences

Clinicians are now trying to treat multiple myeloma similar to leukemia.

Read More

Carol Ann Huff, MD, discusses how to best use newly-approved therapies for multiple myeloma.

Read More

Comparing autologous stem cell transplant with bortezomib, melphalan, and prednisone. 

Read More

News

A comparative effectiveness study analyzed response to anemia supportive treatment for patients with multiple myeloma or lymphoma, published in Supportive Care in Cancer (online November 7, 2017; doi:10.1007/s00520-017-3948-5).

Read More

Next-generation sequencing may help identify patients with smoldering multiple myeloma at high risk for disease progression, suggests a study to be presented at the upcoming American Society of Hematology Annual Meeting and Exposition (December 9-12, 2017; Atlanta, GA).

Read More

A recent study confirmed that administering a higher dosage once-weekly of a common therapy for relapsed or refractory multiple myeloma improves PFS by 3.6 months, compared with twice-weekly administration of a lower dosage.

Read More

Researchers developed a novel gene signature that has prognostic value in patients with multiple myeloma who are treated with immunomodulatory derivatives.

Read More

Quiz

According to a recent study, maintenance therapy with which agent prolongs time to remission after autologous stem cell transplantation in multiple myeloma?

Read More

Research in Review

According to recent research presented at ASCO, adding which targeting agent to standard of care carfilzomib, lenalidomide, and dexamethasone is a safe and efficacious alternative to ASCT for patients with multiple myeloma?

Read More

Targeted therapy against a particular protein has the potential to improve outcomes and fracture-free survival for patients with multiple myeloma.

Read More

Adult patients with multiple myeloma who receive a high-dose chemotherapy regimen plus autologous stem-cell transplantation improve their median progression-free survival by 14 months compared with patients who receive chemotherapy alone.

Read More

Single agent daratumumab may serve as a more cost-effective treatment strategy than pomalidomide for patients with refractory multiple myeloma.

Read More

Subscribe to Hematologic Malignancies